Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET

Company Participants

Naomi Aoki - SVP, Corporate Communications & IR

Bryan Stuart - President & CEO

Judy Dunn - President, R&D

Esther Rajavelu - CFO

Chris Morabito - CMO

Paul Bruno - Executive Director, Corporate Development

Conference Call Participants

Judah Frommer - Credit Suisse

Dae Gon Ha - Stifel

Ted Tenthoff - Piper Sandler

Joseph Schwartz - SVB

Matt Biegler - Oppenheimer

Operator

Good morning and welcome to Fulcrum Therapeutics' First Quarter 2022 Conference Call. Currently all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call.

I would now like to turn the call over to Naomi Aoki, Senior Vice President of Corporate Communications and Investor Relations at Fulcrum. Please proceed.

Naomi Aoki

Thank you. Good morning and welcome to Fulcrum Therapeutics conference call.

Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, clinical development timelines, and financial projections.

While these forward-looking statements represent our views as of today, they should not be relied upon as representing our views in the future. We may update these statements in the future, but we are not taking on an obligation to do so. Please refer to our most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with our business.

With me on today's call are Bryan Stuart, President and Chief Executive Officer; Judy Dunn, our President of R&D; and Esther Rajavelu, our CFO. Chris Morabito, Chief Medical Officer; and Paul Bruno, our Executive Director of Corporate Development will also be available for Q&A.

Let me run quickly through this morning's agenda. Bryan will begin the call with a corporate overview, key updates and review of upcoming milestones. Judy will review our FTX-6058 program, Esther will cover our financials, and then Bryan will open the call for Q&A.

With that, it's my pleasure to turn the call over to Bryan.

Bryan Stuart

Thank you, Naomi. Good morning, everyone and thank you for joining us today.

At Fulcrum, our mission is to treat the root cause of rare genetic diseases and we are advancing two important clinical stage assets that support that mission. The first is our Phase 3 FSHD program that is positioned to be a first-to-market therapy for an untreated patient population. The second is our program for sickle cell disease and other hemoglobinopathies a once daily HbF inducer, with the potential to be the first oral therapy that can broadly improve outcomes for these diseases. We have made significant progress across these programs in the first quarter.